In clinical and preclinical studies, methylone and MDMA show potential efficacy for treating PTSD but with notable differences in their mechanisms of action and observed clinical effects.
• Both act on monoamine transporters, but with different relative potencies. Methylone also appears to have no off-target effects versus MDMA, which acts of 5HT2A, 5HT2B, 5HT2C receptors and others reported in the literature.
• Gene expression studies suggest that MDMA regulates more gene targets than methylone, likely due to activation of 5HT receptors (and others). Overlapping gene changes may reflect those relevant for therapeutic efficacy.